BIOG vs. BGEU, BGS, AAIF, TAM, LWI, CTUK, JAGI, CTPE, HNE, and BIPS
Should you be buying The Biotech Growth Trust stock or one of its competitors? The main competitors of The Biotech Growth Trust include Baillie Gifford European Growth Trust (BGEU), Baillie Gifford Shin Nippon (BGS), abrdn Asian Income Fund (AAIF), Tatton Asset Management (TAM), Lowland Investment (LWI), CT UK Capital And Income Investment Trust (CTUK), JPMorgan Asia Growth & Income (JAGI), CT Private Equity Trust (CTPE), Henderson EuroTrust (HNE), and Invesco Bond Income Plus (BIPS). These companies are all part of the "asset management" industry.
The Biotech Growth Trust (LON:BIOG) and Baillie Gifford European Growth Trust (LON:BGEU) are both small-cap financial services companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability, community ranking and valuation.
Baillie Gifford European Growth Trust has higher revenue and earnings than The Biotech Growth Trust. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than Baillie Gifford European Growth Trust, indicating that it is currently the more affordable of the two stocks.
Baillie Gifford European Growth Trust has a net margin of 117.62% compared to The Biotech Growth Trust's net margin of 0.00%. Baillie Gifford European Growth Trust's return on equity of 8.74% beat The Biotech Growth Trust's return on equity.
In the previous week, The Biotech Growth Trust and The Biotech Growth Trust both had 1 articles in the media. The Biotech Growth Trust's average media sentiment score of 0.76 beat Baillie Gifford European Growth Trust's score of 0.00 indicating that The Biotech Growth Trust is being referred to more favorably in the media.
The Biotech Growth Trust has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Baillie Gifford European Growth Trust has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.
The Biotech Growth Trust received 82 more outperform votes than Baillie Gifford European Growth Trust when rated by MarketBeat users.
26.7% of The Biotech Growth Trust shares are owned by institutional investors. Comparatively, 49.5% of Baillie Gifford European Growth Trust shares are owned by institutional investors. 0.5% of The Biotech Growth Trust shares are owned by insiders. Comparatively, 2.5% of Baillie Gifford European Growth Trust shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Baillie Gifford European Growth Trust beats The Biotech Growth Trust on 11 of the 13 factors compared between the two stocks.
Get The Biotech Growth Trust News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIOG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIOG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
The Biotech Growth Trust Competitors List
Related Companies and Tools
